Shopping Cart

Remove All
Your shopping cart is currently empty

Proceed to checkout Continue shopping

Immunology/Inflammation

Aryl Hydrocarbon Receptor

Immunology/Inflammation related

NOD-like Receptor (NLR)

Prostaglandin Receptor

Reactive Oxygen Species

Thrombopoietin Receptor

Bcl-6

Bcl-6 (B-cell lymphoma 6) is a zinc finger transcription factor that acts as a key regulator of B cell development and immune responses. It functions primarily as a transcriptional repressor, controlling genes involved in cell proliferation, apoptosis, and differentiation. BCL6 is essential for the formation of germinal centers during humoral immunity, where it regulates B cell maturation and antibody production. Dysregulation of BCL6 is associated with lymphomas, particularly diffuse large B-cell lymphoma (DLBCL), where it promotes cell survival and proliferation. Due to its critical role in immunity and cancer, BCL6 is a potential therapeutic target in hematological malignancies.

Filter HomeSignaling PathwaysImmunology/InflammationBcl-6

ARV-393

T843162851885-95-3

ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL).

$223

In Stock

Size

QTY

Glycochenodeoxycholic Acid

T4588640-79-9

Glycochenodeoxycholic Acid (Lithocholylglycine) is a glycine conjugate of lithocholic acid, a bile acid. It is increased in livers of mice that are fed diets supplemented with ursadeoxycholic acid. Glycolithocholic acid levels are decreased in lean mice treated with obestatin. Serum glycolithocholic acid levels increase with age in children.

In Stock

Size

QTY

Cited

BI-3802

T54082166387-65-9

BI-3802, a highly potent BCL6 degrader, targets and inhibits the Bric-à-brac (BTB) domain of BCL6, exhibiting an IC50 value of ≤3 nM. It induces polymerization of BCL6 and facilitates its degradation in a manner dependent on the E3 ligase SIAH1, demonstrating notable antitumor activity[1][2].

$127

In Stock

Size

QTY

ARV-393 HCl

T84316L In house

ARV-393 HCl is an orally active and potent PROTAC targeting BCL6 with antitumor activity for the study of non-Hodgkin's lymphoma.

$226

In Stock

Size

QTY

BCL6-IN-3

T104872253878-44-1

BCL6-IN-3 is a potent BCL6 inhibitor with GI50 of 70 nM in SU-DHL4 cells. BCL6-in-3 regulates cell activation, differentiation, DNA damage and apoptosis, and has antitumor activity.

$117

In Stock

Size

QTY

Glycochenodeoxycholic acid sodium salt

T525916564-43-5

Glycochenodeoxycholic acid sodium salt is a bile salt formed in the liver from deoxycholic acid and glycine that induces apoptosis in hepatocytes. It acts as a detergent, dissolves fats for absorption, and is itself absorbed.

In Stock

Size

QTY

FX1

T40891426138-42-2

FX1 is an effective and selective BCL6 inhibitor (IC50: 35 μM).

In Stock

Size

QTY

Cited

BCL6-IN-6

T600082408882-54-0

BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.

In Stock

Size

QTY

CID5721353

T3940301356-95-6

CID5721353 (BCL6 inhibitor) is a B-Cell Lymphoma 6 Inhibitor (BCL6 inhibitor) that disrupts BCL6/corepressor complexes in vitro and in vivo, and was shown to bind the critical site within the BTB groove.

In Stock

Size

QTY

TL4-12

T262801620820-12-3

TL4-12 is a specific MAP4K2/GCK inhibitor that inhibits IKZF1 and BCL-6.TL4-12 inhibits MM cell proliferation and induces apoptosis, and can be used in the study of multiple myeloma (MM).

In Stock

Size

QTY

BCL6-IN-7

T87312097518-46-0

BCL6-IN-7 (BCL6 inhibitor-7) is a BCL6 co-repressor interaction inhibitor with potential anticancer activity. It can be used for studying lymphomas.

In Stock

Size

QTY

BI-3812

T145612166387-64-8

BI-3812 is an inhibitor of BCL6. Which inhibiting the BTB domain of BCL6 (IC50: 3 nM). BI-3812 also has antitumor activity.

$112

In Stock

Size

QTY

OICR11029

T2050402374711-65-4

OICR11029 is a potent probe for Bcl-6.

Inquiry Price

Size

QTY

EB-TCIP

T206944

EB-TCIP (BAK-04-212) is a bivalent molecule composed of AP1867 and BI-3812. It facilitates the reversible formation of a ternary complex between FKBPF36V and BCL6BTB, thereby recruiting FKBP12F36V-tagged EWS/FLI1 to DNA sites bound by the transcriptional regulator BCL6, rapidly inducing expression of BCL6 target genes such as SOCS2 and CXCL11. EWS/FLI1 is a fusion transcription factor found in Ewing sarcoma. EB-TCIP is applicable for studying transcriptional dysregulation in cancer.

Inquiry Price

Size

QTY

MNN-02-155

T2068053067681-22-2

MNN-02-155 is a bivalent molecular glue that can simultaneously interact with both p300/CBP and BCL6. It effectively induces the activation of BCL6-targeted reporter genes and promotes cell death. This compound is used in the research of diffuse large B-cell lymphoma (DLBCL).

Inquiry Price

Size

QTY

CDK-TCIP2

T201211

DK-TCIP2 is an anticancer agent formed by linking the CDK9 inhibitor SNS-032 and the BCL6 inhibitor BI-3812. This compound exhibits anticancer activity both in vivo and in vitro, making it suitable for research in lymphoma.

Inquiry Price

Size

QTY

BMS-986458

T2063533005272-36-3

BMS-986458 is a highly selective, orally active BCL6 PROTAC degrader. It specifically targets cereblon (CRBN) and the BCL6 N-terminal BTB domain to catalyze proximity-induced BCL6 degradation. BMS-986458 is applicable for research in B-cell non-Hodgkin lymphoma.

Inquiry Price

10-14 weeks

Size

QTY

JWZ-7-7-Neg1

T887713008612-30-1

JWZ-7-7-Neg1, a neighboring transcription chemical inducer (TCIP), serves as a negative control. It exhibits reduced binding capabilities to BRD4 or BCL6 compared to JWZ-7-7, resulting in lower cytotoxicity towards DLBCL cells.

Inquiry Price

Size

QTY

SMRT peptide

TP2772857026-08-5

SMRT peptide, one of the corepressor factors interacting with the BCL6 BTB domain, binds to the BTB domain of BCL6 to enhance its transcriptional repression function. Additionally, SMRT peptide is utilized for studying protein-protein interactions.

Inquiry Price

Size

QTY

CCT374705

T781772640647-90-9

CCT374705, an orally active BCL6 inhibitor, exhibits potent antiproliferative effects in vitro and effectively inhibits tumor growth in a lymphoma xenograft mouse model [1].

Inquiry Price

8-10 weeks

Size

QTY

TCIP3

T2068503067681-36-8

TCIP3 is a bivalent molecular glue (molecular glue) that can simultaneously bind to both p300/CBP and BCL6. It redirects p300 and CBP to activate programmed cell death genes, which are typically repressed by the oncogenic driver BCL6. TCIP3 is useful for studying diffuse large B-cell lymphoma (DLBCL) and is not toxic to untransformed tonsil lymphocytes or fibroblasts.

Inquiry Price

Size

QTY

BCL6 PROTAC 1

T738692257479-54-0

BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) proteolysis targeting chimera (PROTAC) that inhibits the BCL6 cell reporter with an IC50 of 8.8 µM and significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines, making it valuable for tumor-related research [1].

Inquiry Price

Size

QTY

Go to page 1

Page of 1